By Fineline Cube Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical trial of HP515, a Class 1 innovative drug independently developed by the company for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), have met the primary endpoint and key secondary endpoints with high statistical significance.
Clinical Trial Overview
| Item | Detail |
|---|---|
| Drug | HP515 – oral, highly selective THR-β agonist |
| Developer | Hinova Pharmaceuticals Inc. (SHA: 688302) |
| Indication | Metabolic dysfunction-associated steatohepatitis (MASH) |
| Study Design | Phase IIa, randomized, placebo-controlled |
| Treatment Duration | 12 weeks, once-daily oral administration |
| Dose Groups | 40 mg, 50 mg, 60 mg |
Primary Endpoint Results – Liver Fat Content Reduction
| Group | Mean LFC Reduction at 12 Weeks | p-value vs Placebo |
|---|---|---|
| Placebo | 3.5% | Reference |
| HP515 40 mg | >50% | <0.001 |
| HP515 50 mg | >50% | <0.001 |
| HP515 60 mg | >50% | <0.001 |
All three active dose groups achieved statistically significant liver fat content (LFC) reductions exceeding 50%, compared to only 3.5% in the placebo group (P<0.001).
Secondary Endpoint Results
LFC Response Rates
- ≥30% LFC reduction: Significantly higher proportions in all active dose groups vs placebo (P<0.001)
- ≥50% LFC reduction: Significantly higher proportions in all active dose groups vs placebo (P<0.001)
Lipid Profile Improvements (P<0.001 for all comparisons)
- Low-density lipoprotein cholesterol (LDL-C): Significant reduction
- Apolipoprotein B (ApoB): Significant reduction
- Non-high-density lipoprotein cholesterol (nonHDL-C): Significant reduction
- Total cholesterol (TC): Significant reduction
- Triglycerides (TG): Significant reduction
- Small dense LDL-C (sd-LDL-C): Significant reduction
Mechanism of Action & Innovation
- Target: Thyroid hormone receptor beta subtype (THR-β)
- Mechanism: Highly selective and potent THR-β agonist that directly activates downstream gene transcription
- Therapeutic Effects:
- Enhances hepatocyte lipid metabolism activity
- Increases hepatic fat metabolism
- Reduces lipotoxicity
- Classification: Class 1 innovative drug (first-in-class in China)
- Market Status: No THR-β targeting product approved for marketing in China as of announcement date
Market Impact & Strategic Significance
- MASH Market Opportunity: Global MASH/NASH therapeutics market projected to reach USD 40+ billion by 2030, representing one of the largest unmet medical needs in hepatology
- Competitive Landscape: Multiple companies pursuing THR-β agonists globally, including Madrigal’s resmetirom (approved in US); HP515 represents China’s first domestically developed candidate in this class
- Therapeutic Advantage: Dual benefit of significant liver fat reduction coupled with comprehensive lipid profile improvements addresses both hepatic and cardiovascular risk factors
- Commercial Potential: If approved, HP515 would fill a critical gap in China’s MASH treatment landscape and position Hinova as a leader in metabolic liver disease therapeutics
The robust Phase IIa data support rapid advancement to Phase III development, with all three dose levels demonstrating compelling efficacy and establishing a clear dose-response relationship.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations for HP515. Actual results may differ due to risks including Phase III trial outcomes, regulatory decisions, competitive dynamics, and execution of Hinova’s development strategy.-Fineline Info & Tech